Anzeige
Mehr »
Login
Samstag, 29.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
InnoCan Pharma: Weichenstellung in Richtung Humanversuche und Zulassung der LPD-Plattform!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 789617 ISIN: US09062X1037 Ticker-Symbol: IDP 
Xetra
28.01.22
17:35 Uhr
197,96 Euro
-1,34
-0,67 %
1-Jahres-Chart
BIOGEN INC Chart 1 Jahr
5-Tage-Chart
BIOGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
201,40202,2528.01.
201,30202,5528.01.

Aktuelle News zur BIOGEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBiogen Snags $2.3 Billion In Samsung Biosimilars Deal; So, What's Next?5
FrBiogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics2
FrAurinia Pharmaceuticals quick uptick on renewed takeover speculation on Biogen news7
BIOGEN Aktie jetzt für 0€ handeln
FrBiogen Subsides on Sale to Samsung7
FrSamsung buys Biogen out of biosimilar unit for $2.3B-not the whole Aduhelm headache7
FrBiogen's plan to sell stake in Samsung Bioepis is "a step in the right direction" - BofA6
FrThe Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron3
FrUnder the gun with Aduhelm floundering, Biogen sells its stake in biosimilars business for $2.3B10
FrBiogen to sell stake in Samsung Bioepis JV for up to $2.3bn3
FrSamsung buys $2.3 bn Bioepis stake from Biogen to end partnership8
FrSamsung Biologics to acquire Biogen's stake in Samsung Bioepis for $2.3 billion5
FrSamsung Biologics to acquire Biogen's entire stake in Samsung Bioepis for $2.3 billion8
FrSamsung Biologics to acquire Biogen's entire stake in Samsung Bioepis for US$2.3 bln5
FrSamsung Biologics To Buy Biogen's Stake In Samsung Bioepis JV For Up To $2.3 Bln303WESTON (dpa-AFX) - Samsung Biologics agreed to buy Biogen Inc.'s (BIIB) equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion, the companies...
► Artikel lesen
FrBiogen to sell stake in Samsung Bioepis for more than $2 billion6
FrBiogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologics6
FrBiogen Inc.: Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion629The companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) today announced that they have...
► Artikel lesen
DoBiotech Report: Biontech und MorphoSys legen zu; Arrowhead und Biogen vorbörslich fest592(shareribs.com) Frankfurt / New York 27.01.2022 - Biotech-Aktien zeigen sich im schwachen Marktumfeld uneinheitlich. Papiere von Biontech und MorphoSys können deutlich zulegen. Auf der anderen Seite...
► Artikel lesen
DoBiogen/Eisai highlights details for Phase 4 Aduhelm study in Alzheimer's disease7
DoBiogen boosts Aduhelm confirmatory trial amid fight for wider Medicare coverage5
Seite:  Weiter >>
670 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
8,2,11